Table Of Contents:

1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	13
1.2.6 Market Size/Share Estimation	14
1.2.7 Research Limitations	15
1.3 Executive Summary	16
2 Market Overview and Dynamics	19
2.1 Market Size and Forecast	19
2.1.1 Impact of COVID-19 on World Economy	20
2.1.2 Impact of COVID-19 on the Market	22
2.2 Major Growth Drivers	24
2.3 Market Restraints and Challenges	30
2.4 Emerging Opportunities and Market Trends	33
2.5 Porter’s Fiver Forces Analysis	37
3 Segmentation of Europe Market by Offering	41
3.1 Market Overview by Offering	41
3.2 Services	43
3.3 Test Kits & Consumables	44
4 Segmentation of Europe Market by Application	45
4.1 Market Overview by Application	45
4.2 Non-Hodgkin’s Lymphoma (NHL)	47
4.2.1 DLBCL	49
4.2.2 Marginal Zone Lymphoma	50
4.2.3 Follicular Lymphoma	51
4.2.4 Peripheral T-cell Lymphoma	52
4.2.5 Mantle Cell Lymphoma	53
4.2.6 Other NHLs	54
4.3 Multiple Myeloma (MM)	55
4.4 Acute Lymphoblastic Leukemia (ALL)	56
4.5 Chronic Lymphoblastic Leukemia (CLL)	57
4.6 Acute Myeloid Leukemia (AML)	58
4.7 Chronic Myeloid Leukemia (CML)	59
4.8 Hodgkin’s Lymphoma (HL)	60
4.9 Solid Tumor	61
4.10 Other Applications	62
5 Segmentation of Europe Market by Technology	63
5.1 Market Overview by Technology	63
5.2 Flow Cytometry	65
5.3 Polymerase Chain Reaction (PCR)	66
5.4 Next-Generation Sequencing (NGS)	67
5.5 Other Technologies	68
6 Segmentation of Europe Market by End User	69
6.1 Market Overview by End User	69
6.2 Hospitals and Clinics	71
6.3 Research Institutions	72
6.4 Diagnostic Laboratories	73
6.5 Other End Users	74
7 European Market 2021-2031 by Country	75
7.1 Overview of European Market	75
7.2 Germany	78
7.3 U.K.	80
7.4 France	82
7.5 Spain	84
7.6 Italy	86
7.7 Netherlands	88
7.8 Rest of European Market	90
8 Competitive Landscape	92
8.1 Overview of Key Vendors	92
8.2 New Product Launch, Partnership, Investment, and M&A	96
8.3 Company Profiles	97
Adaptive Biotechnologies Corporation	97
ArcherDX, Inc. (Invitae Corporation)	99
Arup Laboratories	100
Asuragen Inc.	101
Bio-Rad Laboratories, Inc.	102
Cergentis B.V.	103
Guardant Health	104
ICON plc	105
Inivata Ltd.	106
Invivoscribe, Inc.	107
Laboratory Corporation of America Holdings	108
Mission Bio, Inc.	109
Natera, Inc.	110
NeoGenomics Laboratories, Inc.	111
Opko Health, Inc.	112
Quest Diagnostics Incorporated	113
Sysmex Corporation	114
RELATED REPORTS	115

List of Tables:

Table 1.  Snapshot of Europe Minimal Residual Disease Testing Market in Balanced Perspective, 2021-2031	17
Table 2. World Economic Outlook, 2021-2031	21
Table 3. World Health Spending by Region, $ bn, 2013-2020	29
Table 4.  Main Product Trends and Market Opportunities in Europe Minimal Residual Disease Testing Market	33
Table 5. Europe Minimal Residual Disease Testing Market by Offering, 2021-2031, $ mn	41
Table 6. Europe Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn	45
Table 7. Europe Minimal Residual Disease Testing Market: Non-Hodgkin’s Lymphoma (NHL) by Type, 2021-2031, $ mn	48
Table 8. Europe Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn	63
Table 9. Main Vendors and Products of Flow Cytometry Technology	65
Table 10. Main Vendors and Products of Polymerase Chain Reaction (PCR) Technology	66
Table 11. Main Vendors and Products of Next-Generation Sequencing (NGS) Technology	67
Table 12. Europe Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn	69
Table 13. Europe Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn	77
Table 14. Germany Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn	79
Table 15. Germany Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn	79
Table 16. Germany Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn	79
Table 17. U.K. Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn	81
Table 18. U.K. Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn	81
Table 19. U.K. Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn	81
Table 20. France Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn	83
Table 21. France Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn	83
Table 22. France Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn	83
Table 23. Spain Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn	85
Table 24. Spain Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn	85
Table 25. Spain Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn	85
Table 26. Italy Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn	87
Table 27. Italy Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn	87
Table 28. Italy Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn	87
Table 29. Netherlands Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn	89
Table 30. Netherlands Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn	89
Table 31. Netherlands Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn	89
Table 32. Minimal Residual Disease Testing Market in Rest of Europe by Country, 2021-2031, $ mn	91
Table 33. Breakdown of World Market by Key Vendor, 2021, %	94
Table 34. Approved and Launched MRD Testing Products of Key Vendors	94
Table 35. Adaptive Biotechnologies Corporation: Company Snapshot	97
Table 36. Adaptive Biotechnologies Corporation: Business Segmentation	98
Table 37. Adaptive Biotechnologies Corporation: Product Portfolio	98

List of Figures:

Figure 1. Research Method Flow Chart	11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation	14
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031	16
Figure 4. Europe Minimal Residual Disease Testing Market, 2021-2031, $ mn	19
Figure 5. Impact of COVID-19 on Business	22
Figure 6. Primary Drivers and Impact Factors of Europe Minimal Residual Disease Testing Market	24
Figure 7.  World Number of Deaths from Cancers in 201	27
Figure 8.  Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million	28
Figure 9. World Population 65 and Over, % of Total Population, 1950-2060	28
Figure 10. Primary Restraints and Impact Factors of Europe Minimal Residual Disease Testing Market	30
Figure 11. Investment Opportunity Analysis	34
Figure 12. Porter’s Fiver Forces Analysis of Europe Minimal Residual Disease Testing Market	37
Figure 13. Breakdown of Europe Minimal Residual Disease Testing Market by Offering, 2021-2031, % of Revenue	42
Figure 14. Europe Addressable Market Cap in 2022-2031 by Offering, Value ($ mn) and Share (%)	42
Figure 15. Europe Minimal Residual Disease Testing Market by Offering: Services, 2021-2031, $ mn	43
Figure 16. Europe Minimal Residual Disease Testing Market by Offering: Test Kits & Consumables, 2021-2031, $ mn	44
Figure 17. Breakdown of Europe Minimal Residual Disease Testing Market by Application, 2021-2031, % of Sales Revenue	46
Figure 18. Europe Addressable Market Cap in 2022-2031 by Application, Value ($ mn) and Share (%)	46
Figure 19. Europe Minimal Residual Disease Testing Market by Application: Non-Hodgkin’s Lymphoma (NHL), 2021-2031, $ mn	47
Figure 20. Europe Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): DLBCL, 2021-2031, $ mn	49
Figure 21. Europe Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Marginal Zone Lymphoma, 2021-2031, $ mn	50
Figure 22. Europe Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Follicular Lymphoma, 2021-2031, $ mn	51
Figure 23. Europe Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Peripheral T-cell Lymphoma, 2021-2031, $ mn	52
Figure 24. Europe Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Mantle Cell Lymphoma, 2021-2031, $ mn	53
Figure 25. Europe Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Other NHLs, 2021-2031, $ mn	54
Figure 26. Europe Minimal Residual Disease Testing Market by Application: Multiple Myeloma (MM), 2021-2031, $ mn	55
Figure 27. Europe Minimal Residual Disease Testing Market by Application: Acute Lymphoblastic Leukemia (ALL), 2021-2031, $ mn	56
Figure 28. Europe Minimal Residual Disease Testing Market by Application: Chronic Lymphoblastic Leukemia (CLL), 2021-2031, $ mn	57
Figure 29. Europe Minimal Residual Disease Testing Market by Application: Acute Myeloid Leukemia (AML), 2021-2031, $ mn	58
Figure 30. Europe Minimal Residual Disease Testing Market by Application: Chronic Myeloid Leukemia (CML), 2021-2031, $ mn	59
Figure 31. Europe Minimal Residual Disease Testing Market by Application: Hodgkin’s Lymphoma (HL), 2021-2031, $ mn	60
Figure 32. Europe Minimal Residual Disease Testing Market by Application: Solid Tumor, 2021-2031, $ mn	61
Figure 33. Europe Minimal Residual Disease Testing Market by Application: Other Applications, 2021-2031, $ mn	62
Figure 34. Breakdown of Europe Minimal Residual Disease Testing Market by Technology, 2021-2031, % of Sales Revenue	64
Figure 35. Europe Addressable Market Cap in 2022-2031 by Technology, Value ($ mn) and Share (%)	64
Figure 36. Europe Minimal Residual Disease Testing Market by Technology: Flow Cytometry, 2021-2031, $ mn	65
Figure 37. Europe Minimal Residual Disease Testing Market by Technology: Polymerase Chain Reaction (PCR), 2021-2031, $ mn	66
Figure 38. Europe Minimal Residual Disease Testing Market by Technology: Next-Generation Sequencing (NGS), 2021-2031, $ mn	67
Figure 39. Europe Minimal Residual Disease Testing Market by Technology: Other Technologies, 2021-2031, $ mn	68
Figure 40. Breakdown of Europe Minimal Residual Disease Testing Market by End User, 2021-2031, % of Revenue	70
Figure 41. Europe Addressable Market Cap in 2022-2031 by End User, Value ($ mn) and Share (%)	70
Figure 42. Europe Minimal Residual Disease Testing Market by End User: Hospitals and Clinics, 2021-2031, $ mn	71
Figure 43. Europe Minimal Residual Disease Testing Market by End User: Research Institutions, 2021-2031, $ mn	72
Figure 44. Europe Minimal Residual Disease Testing Market by End User: Diagnostic Laboratories, 2021-2031, $ mn	73
Figure 45. Europe Minimal Residual Disease Testing Market by End User: Other End Users, 2021-2031, $ mn	74
Figure 46. Breakdown of European Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue	76
Figure 47. Contribution to Europe 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%)	77
Figure 48.  Minimal Residual Disease Testing Market in Germany, 2021-2031, $ mn	78
Figure 49.  Minimal Residual Disease Testing Market in U.K., 2021-2031, $ mn	80
Figure 50.  Minimal Residual Disease Testing Market in France, 2021-2031, $ mn	82
Figure 51.  Minimal Residual Disease Testing Market in Spain, 2021-2031, $ mn	84
Figure 52.  Minimal Residual Disease Testing Market in Italy, 2021-2031, $ mn	86
Figure 53.  Minimal Residual Disease Testing Market in Netherlands, 2021-2031, $ mn	88
Figure 54.  Minimal Residual Disease Testing Market in Rest of Europe, 2021-2031, $ mn	90
Figure 55. Growth Stage of Europe Minimal Residual Disease Testing Industry over the Forecast Period	92

Selected Key Players: 
Adaptive Biotechnologies Corporation
ArcherDX, Inc. (Invitae Corporation)
Arup Laboratories
Asuragen Inc.
Bio-Rad Laboratories, Inc.
Cergentis B.V.
Guardant Health
ICON plc
Inivata Ltd.
Invivoscribe, Inc.
Laboratory Corporation of America Holdings
Mission Bio, Inc.
Natera, Inc.
NeoGenomics Laboratories, Inc.
Opko Health, Inc.
Quest Diagnostics Incorporated
Sysmex Corporation 
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)